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Abstract
Peripheral artery disease impacts greater than 200 million people worldwide and
is the third leading cause of atherosclerotic vascular morbidity. The early stages of the
disease are ideally treated behaviorally with exercise. However, there is poor exercise
adherence due to fear of pain, poor perceived control over the disease, low motivation,
and lack of education surrounding the diagnosis. Imaging has been used to change
exercise behaviors among patients with other diseases, such as coronary artery disease.
This study will test whether allowing participants to see ultrasound images of their
vasculature in response to exercise-associated claudication pain will increase
adherence to 12 weeks of at-home exercise. We hypothesize that using imaging to
create a personalized pain-function scale during the clinical workup will improve patient
exercise adherence and thus increase claudication onset time during exercise. If effective,
this approach may prove to be instrumental to slowing the progression of peripheral
artery disease.

vi

Chapter 1 - Introduction
1.1 Background
Peripheral artery disease (PAD) is a condition where atherosclerosis, plaque
buildup within arteries, reduces oxygenated blood flow through peripheral arteries and
may even lead to thrombosis.1 PAD is classified into several categories based on
symptoms and severity progression: asymptomatic, claudication (pain due to intermittent,
restricted blood flow to the limb during exercise), critical limb ischemia, and acute limb
ischemia.2 Once patients reach the point of critical limb ischemia, they typically need a
surgical intervention.2 However, severe damage occurs before patients reach the stage of
critical limb ischemia.3 For example, patients experience an increased risk for
cardiovascular events beginning in the asymptomatic stage, including myocardial
infarctions, ischemic strokes, heart failure, and vascular deaths.4 Therefore, it is crucial to
control the disease in the early stages. Exercise is known to improve early stage PAD
symptoms and outcomes, but exercise adherence rates are low.1 In attempt to prevent
disease progression and improve symptoms, this research will focus on an exercise
adherence strategy for patients with lower extremity intermittent claudication (IC) PAD.
PAD Prevalence, Health Risks, and Economic Burden
Around 202 million people worldwide have PAD, a 23.5% increase from
2000.5 This increase is due to our aging population and a rise in chronic disease risk
factors.5 PAD has a widespread effect, with 140.8 million (70%) people from low- and
middle-income countries and 61.3 million (30%) from high-income countries.5 In the
U.S., there are 12 million people living with PAD.5 The large burden and widespread
prevalence of PAD demonstrate the urgency to prevent, diagnose, and treat PAD.
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The large number of people impacted by PAD is concerning due to the associated
cardiovascular risks.5 Lower limb PAD is the third leading cause of atherosclerotic
vascular morbidity behind coronary heart disease and stroke.5 Regardless of the stage of
PAD, those with the disease have three times the chance of experiencing major
cardiovascular events.5 These cardiovascular events have high mortality rates; up to 23%
of people with PAD die from coronary or cerebrovascular disease.5 With its large impact
on health, PAD has a significant economic burden. The rate of hospitalization for U.S.
PAD patients in 2014 was 89.5/100,000 with a total annual cost of $6.31 billion.6 More
than half of these patients are discharged to skilled nursing facilities or need home
healthcare, bringing additional costs.6 Improved early treatment options are needed in
order to decrease the significant heath and cost burdens associated with PAD. This is
especially pertinent due to the increasing prevalence of primary PAD risk factors such as
diabetes, hypertension, and hyperlipidemia.7 IC PAD patients are the perfect population
to work with to increase exercise adherence and take control of PAD outcomes early in
the disease.
Intermittent Claudication PAD and Quality of Life
The prevalence of those experiencing PAD-associated IC is around 40 million
worldwide.5 PAD with IC is described as fatigue, discomfort, or pain that arrives with
exercise and dissipates with rest.8 During exercise, muscles have a higher oxygen
demand that cannot be met due to atherosclerosis, leading to the described
symptoms.8 IC is concerning because the symptoms lead to a decreased quality of life
(QOL), and the physiology leads to significantly higher mortality rates.9 Patients with IC
were shown to have an impaired QOL compared to asymptomatic PAD patients and
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those without PAD.9 This study by Dumville et al. administered a health-related qualityof-life questionnaire which revealed that patients with IC had significantly lower physical
functioning, higher physical limitations, higher emotional limitations, lower energy,
higher pain, and lower general health perception compared to patients without
claudication pain.9 Another study found that this poorer QOL was most strongly
predicted by physical function rather than specific markers of disease severity.10 These
findings support the need to improve claudication symptoms which, in turn, is predicted
to improve QOL.
Intermittent Claudication PAD Medical Management
Medical therapy, exercise programs, and surgery are all used to treat patients with
IC PAD.11 Some medical therapies target symptoms, while others are for secondary risk
reduction.11 Even with significant research, only two medications are FDA approved to
improve IC symptoms: cilostazol and pentoxifylline.11 While cilostazol, the more
commonly prescribed medication, has been shown to improve walking performance,
adherence is low.11,12 Less than 40% are adherent to the medication after 36 months
because it comes with adverse effects such as headache, palpitations, and
diarrhea.12 There is little quality data showing the benefits of pentoxifylline, so it has
been given a class 3 recommendation, meaning it is not indicated or useful, for
claudication symptoms.11 In conclusion, medical treatment options remain suboptimal in
providing symptomatic relief or reversal of pathology without adverse effects that lower
adherence.
Similarly, while aggressive medical therapies are effective in reducing the poor
secondary outcomes of PAD such as myocardial infarctions and strokes, adherence rates
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are low.13 Aggressive medical treatment includes antiplatelet agents, statins and lipidlowering agents, and blood pressure control agents.13 Unfortunately, the observational
National Health and Nutrition Survey showed that only 35.8% of PAD patients were
taking aspirin, 30.5% were taking statins, and 24.9% were taking angiotensin converting
enzyme inhibitors.13
The last line of PAD medical treatment is revascularization and amputation
surgeries, which come with a host of risks such as infection, atelectasis, pain, reactions to
anesthesia, and blood clots.14 Since many PAD patients are not taking the medications
needed to improve their outcomes and surgery comes with additional risk and cost
burdens, we need to ensure patients are utilizing other strategies to keep their disease
under control, such as exercise.
Intermittent Claudication PAD Behavioral Management
In direct contrast to the normal exercise advice given to the general public about
using pain as a warning sign to stop exercise, the main behavioral treatment for IC is
exercising to the point of moderate or severe claudication pain.15 With proper treatment,
the progression to critical limb-threatening ischemia and amputation is <10% and <1%,
respectively.11 Unfortunately, despite research showing that exercise helps with PAD
symptoms, those with PAD walk less and at a slower pace compared to those without
PAD.16 This leads to an impaired functional status and to a poorer QOL. Supervised
exercise training (SET) is the gold standard to improve QOL, walking speed, walking
distance, vascular function, and cardiovascular outcomes.16 Unfortunately, it is
challenging to get patients to participate. A systematic review found that 75.8% of
screened PAD patients were not able or willing to participate in SET; common barriers
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were cost, travel time, and access.17 Therefore, we need to find a way to increase
adherence to exercise while avoiding these barriers.
One promising strategy is home exercise programs (HEPs), which could be
implemented on a global level, irrespective of income level. HEPs are more convenient
and low-cost because patients are able to walk at an easily accessible location instead of
traveling to a supervised exercise center. Gardner et al. found that SET increased peak
walking time by 192 seconds, while a structured HEP increased peak walking time by
110 seconds; both statistically significant improvements compared to the control group of
light resistance training.18 The structured HEP utilized a step activity monitor and
monthly meetings.18 Other techniques used in HEPs to increase adherence include goal
setting, keeping an activity log, working with a psychologist, and interacting with a
coach.19 While these motivation tools have been successful, they cost money and take
additional time. There is still a gap in the literature on how to make home exercise more
affordable and maximally time efficient. A potential solution is to motivate patients to
adhere to home exercise prior to when they start, so they will not need lots of additional
resources to keep them motivated throughout.
Novel Use of Imaging for Intermittent Claudication PAD Management
Prior studies have utilized coaches, goal setting, activity logs, and activity
monitors for HEP motivation, but no one has used imaging.18,19 Ultrasound is a
commonly used tool that is noninvasive, fast, simple, and relatively inexpensive. Our
plan is to use ultrasound imaging in order to break down known barriers to exercise
among the PAD population including lack of education regarding the pathology
associated with PAD, fear of claudication pain, lack of perceived control over the disease,
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and lack of motivation.20,21,22 To do so, we will use ultrasound as a way for patients to
visualize their disease state during different levels of exercise-associated pain,
personalizing their pain and condition. If we are able to use imaging in order to increase
exercise adherence among IC patients by allowing them to understand and target a useful
level of pain for their condition this would be a great intervention to incorporate into the
PAD diagnosis appointment. Creating this motivation to exercise prior to starting the
home exercise regimen will help alleviate the need for expensive and timely motivation
tools during HEPs. Overall, establishing this understanding and behavior early on is
intended to slow down the progression of disease.
1.2 Statement of the Problem
Exercise is known to improve IC symptoms and PAD outcomes.1 Evidence
supports SET as the primary treatment, but barriers such as cost, access, and convenience
lead to low adherence rates.17 HEPs are shown to be effective and mitigate these barriers,
but do not completely eliminate them.18,19 Effective HEPs have used coaches, frequent
office visits, and psychologists, but these motivators for adherence still introduce barriers
such as cost and time.18,19 In addition to these barriers, poor understanding of how
walking helps alleviate symptoms, fear of claudication pain, and perceived lack of control
over the disease also contribute to low HEP adherence rates.20,21,22 Therefore, an
intervention that targets all of these barriers is needed in order to increase home exercise
adherence rates. In other medical conditions, using images to improve patient attention
to their diagnosis, comprehension of their disease, and adherence to their treatment has
been effective.23 For example, imaging has been used with coronary artery disease
(CAD) patients to positively change exercise behaviors.23 Therefore, we are proposing
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the use of color Doppler ultrasonography imaging to show patients their personalized
pain scale during exercise-associated claudication in clinic. The intent is to have the
imaging increase home exercise adherence among the IC PAD population.
1.3 Goals and Objectives
The proposed study aims to determine the effect of color Doppler ultrasonography
on exercise-associated claudication onset time (COT) in adults with PAD after 12 weeks
of home exercise. More specifically, prior to 12 weeks of home exercise, we will allow
patients to view their vasculature obtained during different levels of exercise-associated
(during a treadmill test) claudication pain and establish a personalized pain scale.
The primary outcome will be COT, in seconds, during a graded treadmill test in
participants who saw their vasculature on ultrasound compared to participants who did
not see their color ultrasound images. Secondary outcomes will be mean walking
distance, in meters, to reach mild, moderate, and severe claudication pain during the
graded treadmill test, 6-minute walk test distance in meters, peak systolic velocity
(cm/second) through the popliteal artery, average steps per day during home exercise,
health-related quality of life score, fear of claudication pain and physical activity score,
and walking impairment score.
1.4 Hypothesis
Among adults with intermittent claudication peripheral artery disease, we
hypothesize that using color Doppler ultrasonography during an personalized pain-scale
walking assessment will increase adherence to standard of care home exercise for 12
weeks, thus improving their graded treadmill walking test claudication onset time, in
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seconds, from baseline compared to those who did not see their vasculature on
ultrasound.
1.5 Definitions
Color Doppler: An ultrasound setting that allows visualization of blood flow through a
vessel and differentiation from the surrounding tissue.24
1.6 Clinical Significance
It is well-established that exercise improves IC PAD outcomes but inducing
behavior change is challenging. Exercise adherence is especially important right now in
a time when PAD risk factors are increasing. Exercising through pain goes against
everything people are told about exercise, but we believe that showing patients that their
leg blood flow is present during pain should encourage them to push through the pain and
reassure them in order to increase exercise adherence.
In the PAD diagnosis appointment at the Yale New Haven Hospital (YNHH)
Heart and Vascular Center, patients undergo an ABI and pulsed volume recording (PVR)
to confirm the diagnosis, show the location of the lesion, and determine the severity of
the disease. For patients with a normal ABI/PVR at rest, but symptoms consistent with
IC, technicians facilitate a graded treadmill test to induce claudication pain and then
perform an ABI/PVR. The same technicians perform ABI/PVRs, treadmill tests, and
ultrasonography. The fact that the equipment and technician knowledge for our study
already exist at YNHH makes our proposed study feasible to incorporate into the PAD
diagnosis appointment. If it is successful in improving exercise adherence rates and
walking performances, adding a personalized pain-function imaging scale would offer a
step forward to improving morbidity and mortality within this population.
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Chapter 2 - Review of the Literature
2.1 Introduction - Literature Search Criteria
A review of the literature took place from July 2019 to May 2020 using Medline
(used medical subject headings, MeSH), Pubmed, Scopus, ScienceDirect, and PyscINFO.
The key terms used, independently and in combination, to find information regarding
peripheral artery disease, prevalence, pathophysiology, exercise programs, barriers to
treatment adherence, and the impact of imaging on treatment adherence were peripheral
artery disease (peripheral vascular disease, peripheral atherosclerosis, peripheral
arterial occlusive disease, lower extremity arterial disease), prevalence (epidemiology),
risk factors (associated disease), claudication (intermittent claudication, claudication
pain, calf cramping), pathophysiology, supervised exercise training (supervised exercise
programs), home exercise programs (home workouts, walking, exercise), change (modify,
develop), adherence, behavior (habit), barrier (limitation, obstacle), fear (worry),
avoidance, pain, picture (image, imagery), ultrasound (Doppler, ultrasonography, color
mode), perceived control (control), health literacy (health understanding), education
(knowledge), and motivation. They were sorted by relevance or year of publication.
Only articles written in English were used. Articles’ titles and abstracts were
preliminarily used to determine whether an article would be relevant to this review. To
find additional pertinent research, articles cited within studies found during the original
search were used. Most of the articles are meta-analyses, literature reviews, randomized
controlled trials (RCTs), observational, or prospective cohort studies.
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2.2 How Exercise Reduces Claudication Pain
We have known for many years that exercise reduces claudication pain. In 1995,
a meta-analysis with 21 studies showed that exercise training increased pain-free walking
distance by 179% (125.9±57.3m to 351.2±188.7m; p<.001).1 More recently, a study
looked at the underlying mechanisms of PAD.2 Arterial obstruction, endothelial damage,
altered skeletal muscle phenotype, mitochondrial dysfunction, and inflammation were all
factors involved in claudication pain that could be reduced with exercise.2
Until recently, an imbalance in oxygen supply and demand during exercise was
thought to be the only reason for claudication pain.3-8 Arterial stenosis, which
accompanies PAD, does not allow for enough blood flow to properly oxygenate the
muscles.2 While this is true, further research has shown that the physiological
mechanism behind claudication pain is much more complicated.
Exercise helps alleviate claudication symptoms by promoting arteriogenesis and
arterial dilation in hypoxic tissues.5 During exercise, there is increased laminar shear
stress and tangential wall stress acting on the vessel walls which promote collateral vessel
growth and an increase in lumen diameter.5 This leads to increased oxygenation of lower
extremity muscles, which lowers ischemia and decreases future claudication pain.9 In a
healthy artery, the endothelium releases vasoprotective factors, such as nitric oxide, to
regulate arterial flow.10 With PAD, there is endothelial damage, so less nitric oxide is
released.10 With ischemia, the muscle requires increased blood flow, but decreased nitric
oxide production prevents a hyperemic flow response.10 Brendle et al. showed that SET
increased endothelium-dependent flow-mediated dilation by 61% (0.18 ±.03mm to
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.29±.04mm; p<.005) among PAD patients.4 Exercise was shown to increase shear stress,
which stimulated nitric oxide production and allowed for increased bloodflow.4
In PAD, periodic ischemia combined with low physical activity levels reduces
overall skeletal muscle area, decreases muscle density, and increases fat content within
lower limb muscles.6,11 On a more microscopic level, there is increased muscle cell
apoptosis, reduced type I muscle fibers, and reduced capillary density which lead to an
accumulation of metabolites.3,12 These metabolites lead to mitochondrial dysfunction,
which decreases oxygen utilization and accelerates endothelial damage. Exercise has
been shown to reverse ischemic muscle changes and improve mitochondrial function.12
IC PAD patients have chronic inflammation.13 In addition, a cross-sectional study
by McDermott et al. showed that higher levels of inflammatory blood markers, C-reactive
protein and interleukin-6, in PAD patients were associated with poorer 6-minute walk
performance.7 These inflammatory markers increase with short periods of exercise, but
decrease with long-term exercise training.13 Therefore, performing regular exercise is
expected to decrease inflammation and increase walking distances.
There is strong evidence for many mechanisms by which exercise reduces
claudication pain and improves function. This supports the need for adherence to longterm, regular exercise among PAD patients in order to improve symptoms and outcomes.
2.3 Supervised Exercise Training: Strengths and Limitations
Current AHA/ACC guidelines state that supervised exercise training (SET) is the
first-line treatment for IC PAD patients.14 SET includes treadmill training to moderate or
maximal ischemic leg symptoms three times a week for up to six months, with each
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session lasting 30-60 minutes.14 The sessions are located at a hospital or an outpatient
clinic and patients must be under direct supervision of a provider.14
Significant research shows SET is effective in improving claudication symptoms
and PAD outcomes. In the 1995 meta-analysis, those in exercise programs demonstrated
a significantly greater increase in maximum walking distance (255.8m; p=.02) and painfree walking distance (107.1m; p=.02) compared to controls.1 A limitation to this study
is that only 3 of the 21 studies were RCTs.1 However, the results of the three RCTs were
consistent with the results in the 18 nonrandomized, uncontrolled trials.1
A more recent systematic review of 25 RCTs showed similar results where SET
increased maximal walking distance by 180m (95% CI, 130-230m) and pain-free walking
distance by 128m (95% CI, 92-165m) compared to controls given no exercise
instructions.15 A strength of this review is it only included RCTs, but it did come with the
limitation of all reviews: the results were limited by the quality of the original studies.15
The included studies utilized different treadmill protocols to assess walking distances and
the SET protocols involved diverse training components in terms of duration, mode, and
intensity.15 However, the two reviews show consistent results over a long period of time,
supporting the idea that some form of SET is effective in improving PAD symptoms.
Despite the evidence of SET improving claudication symptoms, participation
rates in these programs are low. A systematic review found that only 24.2% of IC PAD
patients screened for SET were able or willing to participate.16 It is important to note that
the review included 67 trials, but only 23 gave screening information; this limits the
application of the results.16 Additionally, only 13 of the 23 studies gave specific reasons
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for screening failure.16 However, it still allowed for the analysis of 1,820 subjects, which
provides some evidence of participation rates and reasons for screening failure.16
From the studies that reported the reason for screening failure, 30.6% of patients
were not interested or refused to participate, 16.2% had comorbidities affecting their
ability to exercise, 11.7% of patients were unable to attend SET classes due to distance or
timing, and .2% did not participate due to inadequate insurance coverage.16 Participation
rates were expected to rise in 2017 when Medicare and Medicaid started covering SET,
but this systematic review was performed in 2016, so even prior to insurance changes,
coverage was the least common reason for nonadherence.16
The SET adherence review included all 67 articles.16 Of the 4,012 subjects who
agreed and participated in SET, 3,015 (75.1%) adhered to and completed the
regimen.16 The most common reason for drop out of the SET was lack of motivation
(29.2%).16 Other reasons were patient choice (16.7%), lack of results (8.2%), travel
problems (3.8%), and time or family/work commitments (2.8%).16 The main limitation
to these results is that none of the articles defined the number of sessions needed for SET
completion, so it may have meant attending all sessions or just a few.16 Additionally,
those who agreed to participate likely had a higher baseline level of motivation, which
may have introduced selection bias.16 This is hard to avoid in exercise trial studies, but it
impacts the external validity of the study. While the results of this review were limited
by the methods of the included studies, it still gave a current picture of SET adherence
rates and is one of the few studies that has directly analyzed adherence. These results
show that there are significant barriers to SET participation and adherence, indicating that
a more appealing, motivating, and convenient solution is needed for patients.
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2.4 Home Exercise Programs: Strengths and Limitations
AHA/ACC guidelines give home exercise programs (HEPs) a class IIA
recommendation, meaning the treatment is reasonable and has been found useful based
on evidence from RCTs.14 The appeal of HEPs is they are low-cost, accessible, and
efficient compared to SET programs. A recent meta-analysis showed that HEPs were
effective in increasing walking distances, but it is important to look at the details of how
these programs achieved positive results.17 Evidence indicates that increasing walking
distances via HEPs requires more than simply telling patients to go home and exercise.
In 2011, Gardner et al. compared the efficacy of a HEP versus SET to increase
claudication onset time (COT) and peak walking time (PWT) in participants with IC.18
HEP and SET participants walked to near-maximal claudication pain three days a week
for 12 weeks.18 The HEP group wore a step activity monitor during exercise and had an
in-person meeting with an exercise physiologist every two weeks to discuss their progress
and plan.18 HEP and SET both significantly increased COT (HEP 204s to 337s, p<0.001;
SET 196s to 361s, p<0.001) and PWT (HEP 402s to 526s, p<0.01; SET 325s to 540s,
p<0.01) compared to the control group (COT 225s to 209; PWT 505s to 494s) who was
told to exercise more than usual.18 HEP and SET results were not significantly different
from each other (P>.05).18 While this study suggests that HEP, with proper motivational
tools, can be just as effective as SET in producing statistically significant results, it did
not discuss whether the difference in mean change from baseline between SET and HEP
groups (31s higher in SET for COT, 91s higher in SET for PWT) was clinically
significant.18 Clinical significance is important because the goal is to stop the
progression of the disease and make a meaningful change in participants’ daily life.
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A recent RCT showed that HEPs make positive changes within the vasculature,
similar to those of SET discussed in the prior section.19 The study found that HEPs
significantly decreased endothelial cell apoptosis (1.11 arbitrary units, AU to .77 AU; p
=.016), increased circulating HORAC (an antioxidant; .95 AU to 1.19 AU; p =.005),
increased VEGF-A (26 pg/mL to 35 pg/mL; p =.003), decreased E-selectin (36 pg/mL to
35.5 pg/mL; p= .04), and decreased blood glucose (100 mg/L to 90 mg/L; p=
.041).19 These changes increase antioxidants, induce angiogenesis, decrease
inflammation, and lower blood glucose values.19 A limitation to note is the study did not
follow the participants after trial completion to determine whether the changes altered the
long-term progression of PAD.19 However, the results suggest that if participants
continue to exercise, they will continue to reverse vascular damage.
The benefits of HEPs stated above required motivational techniques, such as
meeting with a coach, motivational interviewer, or an exercise physiologist which comes
with time, cost, and convenience barriers.17 A more recent trial studied whether HEPs
could significantly increase walking distances without in-person visits.20 In 2018,
McDermott et al. studied whether a HEP utilizing a wearable activity monitor and
telephone coaching could significantly increase walking distances among PAD
participants.20 The results showed no significant difference (p=.31) between HEP
participants (5.5 m mean change from baseline) and controls (14.4 m mean change from
baseline) at 9 months during a 6-minute walk test (MWT).20 However, this intervention
was missing several components that may have limited the results. Participants did not
receive immediate coaching feedback after uploading exercise data.20 While this may
have led to significant results, it creates a more challenging intervention to conduct and
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would be less feasible in the general population. Additionally, the adherence rate (79%)
to coaching phone calls within the exercise intervention group may not have been
sufficient for significant results; this represents the realistic challenge of adherence with
this type of intervention.20 However, 79% is still relatively high for exercise programs,
suggesting there may be another factor responsible for insignificant results, such as
insufficient patient understanding of appropriate exercise intensity. These findings
suggest that telephone coaching for a HEP is not effective, demonstrating the continued
need to find a way to increase walking distances without regular in-person visits.
2.5 Poor Health Literacy and Disease Understanding as a Barrier to Change
In 2003 The National Assessment of Adult Literacy found that 35% of the
population had basic or below basic health literacy as measured by clinical, prevention,
and navigation of the health care system domains.21 Healthcare is full of its own
vocabulary and complex topics making it difficult to understand. Americans struggle to
understand medication instructions, appointment reminders, discharge instructions, and
health education materials, leading to a lack of adherence to treatment and poor
management of diagnoses.22 Consistent with this, an observational study showed that
PAD patients are often not aware of the risk factors contributing to their disease.23 Only
31% of the diabetic PAD patients knew that diabetes was a risk factor for PAD.23 The
results were similar for smoking, hypercholesterolemia, and hypertension patients where
only 58%, 25%, and 10% of PAD patients knew these were risk factors for their PAD.23
In a more recent qualitative study, IC PAD patients underwent focus group
discussions about experiences living with PAD, attitudes and beliefs about PAD, and
opinions for behavior change interventions.24 Most patients could define PAD, but were
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unable to define claudication.24 Patients thought diagnostic appointments are too short
and lack follow-up, leading to confusion about the disease.24 Most patients knew that
exercise was suggested, but were unclear on how much and whether it works.24 The most
common barriers to physical activity were pain, fear of leg damage by walking a lot, and
lack of motivation.24 Patients stated that if they were convinced that walking would help
prevent progression of their disease, and if they were able to see improvement, they
would be more motivated.24 Given the nature of qualitative studies, this study was
limited by a small sample size and potential biases that come with compiling individual
responses into conclusive statements.24 However, bias was minimized by having three
researchers review the responses and agree upon identified themes and trends.24
Taken together, these studies reflect the need for better patient education. It
appears that PAD patients would be more motivated to make changes if they understood
the risk factors, pathophysiology, and logic behind the treatment plan for their disease.
Integrating patient education into the diagnostic appointment through a personalized
image-guided exercise test may be an opportunity to increase PAD patient exercise
adherence. Patients would see blood flow in their leg both with and without pain but
would be able to see it is limited. This would give patients a better understanding of their
disease etiology and the need for collateral vessels and increased vessel diameter in order
to increase blood flow and therefore increase function and reduce pain during exercise.
2.6 Fear as a Barrier to Change
There is an association between pain beliefs and treatment adherence, supported
by the fear-avoidance model.25 This model states that negative beliefs and
misunderstanding regarding an activity can lead to fear and avoidance of that
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activity.25 To examine fear in the context of PAD, Sharath et al. performed a pilot study
with 19 participants.26 Participants had underlying fear and misunderstanding regarding
their pain.26 Sixty-three percent of participants thought the primary etiology of their leg
pain was walking (and not due to atherosclerosis), 56% thought physical activity would
harm their legs, 30% thought they should not perform physical activity because it will
make their pain worse, and 30% thought they could not perform physical activity because
it will make their pain worse.26 Authors stated they found “a significant association
between fear-avoidance beliefs and expected benefit from exercise (p=.01)”.26 While the
study suggests that people who have less fear about walking expect a greater benefit from
walking, the small sample size did not allow the study to account for confounders; this
threatens the internal validity of the study.26 Based on this limited information, fear
appears to play a role in PAD exercise adherence, but more studies are necessary to
understand the potential confounding variables.
In conclusion, this study suggests that PAD patients misunderstand the etiology
and fear their pain, they do not understand the benefit of walking, and those with
worsened symptoms have a higher fear-avoidance score.26 These results, in combination
with those from the prior section, emphasize the importance of improving education
among PAD patients about their disease to increase adherence to exercise treatment.
2.7 Increased perceived control leads to better outcomes
Perceived control refers to one’s belief about the ability to influence future life
outcomes.27-31 Those with higher levels of perceived control over their health have
healthier behaviors.31 While there has not been extensive research on perceived control
and PAD specifically, a cross-sectional study in 2014 suggests that perceived control is
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an important indicator of functional health and cardio-metabolic risk.32 They used a scale
of 1 to 6 to rank patients’ level of perceived control.32 For each one point increase on the
scale, grip strength increased by 0.95 kg, hemoglobin A1c decreased by 0.04%, HDL-C
levels increased by 0.92 mg/dL, pulse rate decreased by 0.62 beats per minute, and
weight circumference decreased by 0.24 inches.32 Higher perceived control led to
significantly more physical activity when compared with lower perceived control.32
Physical activity was a mediator between perceived control and markers of functional
health and cardio-metabolic risk.32 Therefore, increased perceived control increased
physical activity, which improved functional health and lowered cardio-metabolic risk.
Perceived control in PAD patients was prospectively examined with statements such as “I
am in control of my ability to walk for exercise”.33 Rejeski et al. found patients with low
control ratings had significantly lower 6-MWT distances (1.41, 1.62, and 1.78 were the
perceived control scores among participants who had low (976 ft), middle (between 976
and 1,285 ft), and high (≥1286 ft) 6-MWT distances; p = 0.0179).33 This latter study is
one of a few studies that has analyzed perceived control in the area of PAD, so the results
need to be further studied in a RCT.33
Our goal is to increase the perceived control patients have over their exercise
behavior and disease by allowing them to see the exercise response of their own
vasculature, personalizing their pain-scale, and showing them improvement overtime
with exercise. This increased perceived control should increase exercise adherence.
2.8 Using Imagery to Increase Education and Motivate Treatment Adherence
Appointments are short, medical terms are confusing, there is a lot of information
provided in a single appointment, and patients are afraid to ask questions with the fear of
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appearing uneducated. These challenges are not likely to change, so we must find
another way to educate patients. Using imaging seems to be a promising next step.
Findings from a RCT demonstrated that patients who were shown a picture with
text about their disease, instead of just text, had improved attention to, comprehension of,
recall of, and adherence to health information.34 Patients who presented to the
emergency department (ED) with a laceration were given a pamphlet for wound care with
either pictures and text or just text.34 Three days later they were asked if they had read
the pamphlet (attention), particular questions about the information (comprehension), and
if they had performed wound care (adherence).34 Ninety-eight percent in the picture
group read the instructions, 46% answered the comprehension questions correctly, and
77% adhered to wound care, which were all significantly better proportions compared to
79%, 6%, and 54% in the text-only group.34 This study had 400 eligible patients, but
only 234 were included in the analysis because the rest were unavailable by telephone for
follow-up.34 However, those who were unavailable were not significantly different in
demographics, time present in the ED, or level of treating physician, so it is less likely to
have impacted the external validity.34 Another limitation is the data relied on selfreported information; this potentially allowed for bias because the patients may have felt
pressured to tell the interviewers what they wanted to hear.34 However, it was a RCT
with interviewers blinded to which group the patients were in, lowering the risk of bias.34
Overall, this study supports the use of images for diagnosis and treatment information.
A prospective cohort study analyzed the best way to present information via
pictures.35 They found using prompts helped participants interpret the picture correctly.35
For example, circling the most important part of the image increased comprehension
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because it helped the patient focus.35 Next, having an underlying understanding of what
the picture was showing led to the best improvement in understanding; pictures enhanced
understanding instead of creating an understanding.35 Pictures helped show changes over
time, how medicine affected the body, and how behavior affected health.35,36 Lastly,
simple drawings using lines and color allowed for better patient understanding compared
to complex images in black and white.35 These concepts will be utilized in this study as
we use color Doppler ultrasonography to provide a simple image to participants in order
to link exercise-associated leg pain (or not) with blood flow (color) in their own leg,
increase disease attention and comprehension, show how behavior impacts health, and
show vascular changes overtime.
Ultrasound imaging has been used previously among the smoking population to
see if visualizing atherosclerosis increased smoking cessation rates.37 Seventy-nine
smokers did not see their ultrasound imaging and only received smoking cessation
counseling, 20 smokers saw their imaging and did not have atherosclerosis, and 54
smokers saw their imaging and had at least one atherosclerotic plaque; six months later,
6.5%, 5.0%, and 22.2% of each group, respectively, had quit smoking.37 Those who saw
their plaque had significantly higher quit rates (p = .003).37 A limitation of this study is
they relied on self-report for smoking cessation which comes with the risk of recall bias
or stating answers to please the interviewers.37 However, the risk of bias should be
similar among intervention groups, so it should not significantly change cessation rates
among groups.37 Additionally, their six-month follow-up does not guarantee that
smoking behaviors would not resume, but prior research states this timeline is sufficient
for cessation studies.37 While our outcome of interest is different, both exercise and
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smoking behaviors are challenging to change. Their success of creating behavior change
using ultrasound to reveal atherosclerosis is extremely promising for our proposed study.
More recently, a study using more advanced diagnostic imaging modalities helped
patients better understand their disease state, as well as helped increase exercise
adherence.38 Electron beam computed tomography (EBCT) was used to detect coronary
artery disease (CAD) and predict cardiovascular risk.38 EBCT allowed patients to
visualize calcium within their coronary arteries, which initiated behavior change.38
Patients saw the calcium in their coronary arteries and were told whether it was mild,
moderate, or severe atherosclerosis.38 Those with atherosclerosis were significantly more
likely to have aspirin initiation (2.98 OR, CI 1.83-4.83), diet changes (2.66 OR, CI 1.634.32), and increased exercise (2.03 OR, CI 1.26-3.27) compared to those without
atherosclerosis.38 These results are replicated in other CAD studies, supporting the idea
that showing patients their vasculature promotes exercise adherence and other riskreducing behaviors.39 Together, these studies support the use of imaging as a promising
next step to increase PAD patients’ disease understanding and exercise adherence.
2.9. Review of Relevant Methodology
2.9.1 Standard of Care
Current AHA/ACC guidelines state SET is the first-line treatment for IC PAD
patients, but SET prescription and adherence rates are low.14,17 For this reason, SET is
the gold standard management, but not the standard of care. A systematic review of 25
RCTs looked at SET among IC PAD patients and found that most of the control groups
were told to walk as much as possible at home, but were not given any specific
instructions.15 Similarly, within a meta-analysis of 11 RCTs that examined the benefits
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of HEPs, control groups were told to walk at home, but were not given specific
instructions.17 While the exact wording may vary, this is the type of advice that patients
receive during follow-up vascular appointments.18 Since our study will take place at
YNHH Heart and Vascular Center, home exercise instructions given to the participants
within this study will be similar to the standard of care exercise instructions given by
their providers. We expect this to be similar to the advice given in prior studies.
It is important to note that the standard of care does not typically include any
motivational components to encourage exercise. As previously mentioned, McDermott et
al. sought to determine whether a wearable activity monitor combined with telephone
coaching would increase walking distances.20 They found no significant difference in 6minute walking distances among experimental and control groups.20 We will provide an
activity monitor to all participants in our study to record home walking distances. Given
the data from McDermott et al., we do not anticipate this significantly impacting the
exercise outcomes of either group; if it does, it should be similar among groups.20
2.9.2 Level of Claudication Pain to Stop Walking
There is mixed evidence on the necessary pain level threshold that people with IC
PAD must reach to improve outcomes. The 1995 meta-analysis looked at 21 studies
where 15 had participants exercise to claudication onset or slightly beyond, and 6 studies
had participants exercise to near-maximal claudication pain.1 The post-intervention
claudication onset distance was significantly higher when participants walked to nearmaximal claudication pain compared to onset of pain, 350.2m (±246.2m) and 104.7m
(±91.2m) respectively (p=.007).1 This suggests that people should be encouraged to
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exercise to near-maximal claudication pain to best improve symptoms. Again, it is
important to keep in mind that only 3 of the studies within this meta-analysis were RCTs.
More recent data reveals conflicting evidence. A systematic review in 2011
looked at 36 RCTs and showed that pain-free exercise significantly increased walking
distances (ranging from 45-71% with relative effect size of 1.54 to 2.91) as did walking
to mild, moderate, or maximum pain (ranging from 52-189% with relative effect size of
.93 to 3.53).40 None of the reviewed studies directly compared pain-free walking versus
walking to mild, moderate, or maximal pain, but these results suggest that exercising to
any level of pain increases walking distances.40
The most recent study exploring what level of claudication pain is best to stop
exercising was performed by Novaković et al. in 2019.41 This RCT found that both
moderate-pain and pain-free groups improved claudication onset distance (moderatepain: 50m to 107m, p = .005; pain-free: 53m to 128m, p = .003) and absolute walking
distance (moderate-pain: 85m to 194m, p =.005; pain-free: 92m to 163m, p = .003), but
only the moderate-pain group had significantly improved vascular function.41 Vascular
function was represented by flow-mediated dilation (FMD; 4.4% to 8%; p = .002) and
pulse-wave velocity (PWV; 6.6 m/s to 6.1 m/s; p = .013).41 On a 5 point pain scale, with
3-4 consistent with moderate to severe pain.41 This is a subjective way to measure pain
and it hard to replicate from day to day; this is a limitation we hope to address in this
proposed study. Another limitation was the small sample size, 29 patients, which created
an underpowered study to detect differences in secondary variables such as FMD and
PWV.41 However, small sample sizes are common in PAD exercise trials because
motivation is low.17 Overall, this is a novel study that provides information on the most
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appropriate pain level to stop exercise to improve exercise distances and improve
vascular function.
Given the conflicting data and the fact that many of these studies were analyzing
SET, it is challenging to come to a conclusion on what level of pain we should include in
the standard of care exercise instructions for the participants in this study. This
inconclusive data also suggests that providers are most likely giving different pieces of
advice to their patients. We will instruct patients to exercise to near-maximal
claudication pain in our study to increase the chance of improving vascular function.
2.9.3 Length of Intervention
A meta-analysis of PAD HEPs showed great variability in the lengths of study
interventions, from 6 to 36 weeks.17 There is not a known relationship between program
length and effectiveness, and there has not been a study comparing the length of the
program for HEPs like there has been for SET.15 For SET, a meta-analysis showed a
significant increase in MWDs for short (4-11 weeks), medium (12-26 weeks), and long
(>26 weeks) interventions compared to the standard of care.15 However, medium-length
interventions increased MWD from baseline (223m; SD 149-298m) significantly more
than short-term (123m; 41-204m) and long-term (145m; 27-263m) interventions.15 These
results were not confirmed by meta-regression analysis and thus need to be studied in a
RCT, but they suggest that a medium length intervention is best to create significant
results.15 However, the long-term intervention results question whether changes made in
medium length interventions will be sustained after intervention completion; we hope to
create change that can be seen quickly within 12 weeks, but also changes patients’
mindset about their disease to change their long-term lifestyle. To do so, we will have
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participants return after 12 weeks to see their improvements which should help reinforce
the level of motivation and create long-term behavior change.
As previously discussed, Gardner et al. performed a 12-week study, within this
medium length category, comparing a HEP, SET, and usual care.18 They found that both
the HEP and SET significantly increased COT and PWT compared to the control group.18
HEP and SET results were not significantly different from each other.18 This indicates
that exercising 3 times a week for 12 weeks is long enough to show significant change
among not only SET, but also HEPs. While previous studies have not specifically
explored HEP intervention length, 12 weeks seems to be the standard for SET and
enough time to see improvement with HEPs. The proposed study home exercise
component will be different than structured HEPs because it will not be using a form of
motivation during the 12-week course, it will have the motivational piece prior to home
exercise. However, we hope to induce exercise changes similar to structured HEPs, so
exercising 3 times a week for 12 weeks should still be a sufficient amount of time to see
exercise adherence changes if the motivational piece is effective.
2.9.4 Transferring Near Infrared Spectroscopy Protocol to this Intervention
In 2019, Murrow et al. used near infrared spectroscopy (NIRS) to determine
whether using tissue hypoxia levels as an endpoint for exercise training is better than
using pain levels for PAD patients.42 NIRS is a non-invasive method that uses the
absorption of reflected light to measure oxygen levels within an active muscle.42 This
study is relevant to our methods because the authors fastened the NIRS device to the
participants’ legs to obtain data in real time.42 This is very similar to how we will be
fastening an ultrasound probe to participants’ legs to get continuous imaging. In order to
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limit the motion artifact in the NIRS signal during a graded treadmill test (GTT), the
NIRS optode was secured to the calf using Velcro straps and bioadhesive tape.42 Our
study will use the same techniques to fasten the ultrasound probe to participants’ legs
during a GTT in order to obtain continual data; it is encouraging that another study was
able to perform a similar setup and obtain quality results. The proposal here is novel for
performing graded-exercise in PAD with pain-scaling and continuous ultrasonography.
2.9.5 Using a Graded Treadmill Test to Obtain the Primary Outcome
The primary outcome in most HEP trials is walking performance assessed by a
treadmill (constant-load or graded) or a corridor-walking test (6-MTW).43 There has
been great controversy in cardiovascular medicine about whether the 6-MWT or
treadmill test is a better functional test for PAD patients.
McDermott et al. performed a RCT where they used a 6-MWT and a treadmill
test to evaluate an exercise intervention; the between-group change comparisons of the
exercise and control groups were statistically significant for both the 6-MWT and
treadmill test.43 However, the estimated effect size of the 6-MWT was .70, while the
treadmill test was 1.01.43 This implies that the treadmill test would need fewer patients
than the 6-MWT to show statistically significant results. Another benefit of the treadmill
test over the 6-MWT is it is able to show submaximal and maximal performance as the
grade increases, while the 6-MWT only shows submaximal walking endurance.44 Lastly,
the 6-MWT is self-paced, so it is not as standardized.45 The treadmill test will allow for a
direct pre- and post-intervention comparison of speed and grade for specific pain levels,
performance, and ultrasonography measures which is not possible when using the 6-
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MWT. For these reasons, this study will use treadmill walking over corridor walking as
the primary testing format, but also collect 6-MWT results per standard clinic testing.
There are constant-load (constant speed and grade) and GTTs (constant speed
with increasing grade).45 The most common GTT starts at 2mph, 0% grade and increases
by 2% every 2 minutes.45 The problem with the constant-load test is the inability to
assess the wide range of PAD patient functionality.45 This protocol may be too
challenging for those with severe PAD, or it may take too long to reach claudication pain
in those with earlier stages of PAD.45 The GTT is able to test a range of PAD patients
because it starts at an easy level and increases to a challenging level in a standardized, but
relatively short period of time.45 This GTT construct lends itself well to the intent of this
proposed study: to establish a personalized exercise-associated pain-scale.
There have been questions regarding whether a treadmill test performance
correlates with non-treadmill ambulatory function and QOL. Research shows that GTT
performance is correlated with Walking Impairment Questionnaire (WIQ) results.46 The
WIQ provides information regarding walking distances and speeds and severity of calf IC
pain during walking.46 A study showed that a change in 0.1 on the WIQ score
corresponded to a 345-meter change in treadmill walking distance with exercise
training.46 This correlation between patient-reported outcomes and treadmill test results
shows that the treadmill is a good marker of the patients’ function off the treadmill. For
these reasons, this study will use a GTT to obtain the primary outcome, COT.
2.9.6 Inclusion and Exclusion Criteria
The main inclusion criterion for IC PAD studies is typical claudication pain:
exertional calf pain that begins with walking and resolves within 10 minutes of rest.14
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Studies have used different ways to define claudication pain. One way is to use the
Rutherford Classification System, which uses only patient-reported symptoms.17 Gardner
et al. used symptoms and diagnostics: history of any type of exertional leg pain,
ambulation limited by leg pain consistent with IC, and an ABI  .90 at rest or  .73 after
exercise.18 We will use this more objective approach to ensure the pain has a vascular,
not neurogenic, origin.

Additionally, participants must have stenosis within the

popliteal artery, confirmed by ultrasound. This has not been included in other studies,
but ensuring the location of the stenosis is just upstream of the calf is important for
patients to connect their calf pain to their vasculature imaging.
PAD exercise trials consistently excluded patients with physical impairments
other than PAD because they prevent the study from measuring how effective the
intervention is in improving claudication symptoms.47,48 These physical impairments
include leg amputations, confinement to a wheelchair, and critical limb ischemia or a foot
ulcer.47,48 Cardiovascular risks such as unstable angina, severe CAD, myocardial
infarction, transient ischemic attack, or stroke within 3 months of screening are common
exclusion criteria because the exercise regimen could induce a cardiovascular event.47,48
Participants who started cilostazol or pentoxifylline within 3 months of the trial start are
typically excluded because these drugs may be responsible for a change in claudication
symptoms instead of the exercise protocol.47,48 Those with serious medical conditions
such as active cancer, class III or IV heart failure, renal failure, liver failure, or blindness
are commonly excluded because participants may be too sick to complete the trial.47,48
Lastly, those with uncontrolled type 2 diabetes mellitus, defined as a hemoglobin A1c
(HbA1c) level greater than 8%, will be excluded from the study.49 This has not been a
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typical exclusion criterion in other studies, but since diabetes is associated with vascular
abnormalities such as vascular inflammation and endothelial cell dysfunction,
uncontrolled diabetes may inhibit the vasculature from making changes with exercise and
thus inhibiting improvement in symptoms.49 While this list of exclusion criteria limits the
external validity of the results, it also decreases confounders and increases the chance of
seeing an effect from the exercise protocol.
2.9.7 Sample Size
The sample sizes among the reviewed PAD exercise training trials are variable,
but the majority of them have small sample sizes (n= 20-50).17 Obtaining large sample
sizes for exercise training studies among the PAD population is challenging, mainly
because motivation is low.16 This study will likely face the same challenge because the
motivational piece is after the patients have agreed to participate. In addition to large
sample sizes, low attrition rates are also hard to obtain. The Gardner et al. study had an
attrition rate of 23% where 80% of these participants dropped out due to disinterest and
lack of motivation; the rates are similar among other studies.47 However, we expect the
nature of this proposed study to reduce these rates, so we will only be accounting for a
10% drop out rate.
The average of other studies that strived to improve COT increased it by 99s to
132s.17 However, a study most closely resembling our proposal was conducted by
Duscha et al. and included 20 participants.50 They used a mobile health intervention and
increased the COT by 205s.50 This study will be used to base our sample size
calculations.
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2.10 Possible confounding variables
Thirty percent of PAD patients have type 2 diabetes mellitus (T2DM); it is the
most common risk factor.51 Therefore, we expect many participants in this proposed
study to have T2DM. Since this is a RCT, participants with T2DM are expected to be
balanced between groups. However, a controlled diabetic with a HbA1c of 6% has
different vasculature than a diabetic with a HbA1c of 8%. This is especially true for
those who have had diabetes for many years. It will be challenging to equally distribute
participants based on HbA1c levels and years since diabetes diagnosis. For example, one
may have a HbA1c of 6%, but from 20 years ago to 6 months ago, when one decided to
get it under control, the HbA1c may have been 12%. For those who have had poor
control for a long period of time, it will be difficult to reverse vascular damage and
therefore improve symptoms. We will be measuring HbA1c levels during the screening
appointment and we can use this information for randomization, but this will only
represent the past 3 months. For this reason, glucose control and years since diabetes
diagnosis may be confounders in this study. Since such a large portion of PAD patients
have T2DM, it will not be part of the exclusion criteria; this would extremely limit the
external validity. However, those with uncontrolled T2DM, HbA1c of >8%, will be
excluded because they will be less likely to produce positive outcomes. Additionally,
those with debilitating peripheral neuropathy will be excluded because this may limit
their walking ability instead of claudication pain.
The type and amount of terrain available for exercise is known to be a barrier to
exercise in PAD patients.52 We will be excluding participants who do not have any place
to exercise, but for those included, the terrain type may vary. Those who have more

33

available green space may be more motivated to exercise and for longer periods of time.
Additionally, including hills in home exercise may improve GTT performance. Lastly, if
the study occurs in the winter, those who do not have access to a gym may be less
motivated to exercise outside in the cold. For these reasons, the amount of space available
for exercise and the terrain type during home exercise may be confounders for this study.
This study relies on taking the clearest images possible during claudication pain in
order to show the participants afterwards. The ability to do so depends on the capability
of the technicians and the patient anatomy; for this reason, these are confounders.
Additionally, since this is a motivational study, the tone of voice of the researcher when
explaining the ultrasound images may impact how the participant feels. For example, an
encouraging tone may reassure the patient about what they are seeing and may impact
their motivation to exercise at home. These types of variables when showing participants
their images are potential confounders that will be addressed by only having the primary
researcher explain the images and by having a script to say to patients.
2.11 Conclusion
The data presented strongly supports the idea that exercise improves claudication
symptoms and PAD outcomes through many different mechanisms.2 SET is the gold
standard treatment, but adherence rates are extremely low.14,16 HEPs have been used to
try to find ways to increase adherence by alleviating some of the exercise barriers.17
Unfortunately, the HEPs that have been effective use motivational components that
increase cost, decrease accessibility, and decrease efficiency.17 In addition to these
barriers it is clear that fear of pain, lack of knowledge, and lack of perceived control over
the disease are also contributing to low exercise adherence.23,24,26,32,33 As PAD prevalence
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rises, we must find a way to increase exercise rates among the PAD population. While
changing behavior is extremely difficult, there is data to suggest that using imaging may
be a good solution.
Images have improved attention to, comprehension of, and recall of health
information.34 This increased understanding will likely increase perceived control and
decrease fear-avoidance behaviors, thus targeting several barriers of exercise
adherence.26,27 Furthermore, imaging has already been found to increase exercise
adherence among CAD patients.39 For these reasons, using imaging to increase patients’
understanding about their disease and exercise adherence among PAD patients is a
promising next step.
The proposed study will use simple, color Doppler ultrasound images to enhance
patients’ understanding of their PAD by showing how it impacts their affected leg during
a personalized, exercise-associated graded pain scale test. If successful, increased
understanding will alleviate fears regarding their pain and motivate them to increase their
exercise adherence to appropriate levels of pain during 12 weeks of exercise typically
instructed by providers as a starting point. This would allow for the motivational
component to be given early on in during the diagnosis appointment, therefore helping to
prevent disease progression.
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Chapter 3 - Study Methods
3.1 Study Design
We will use a single blinded randomized controlled clinical trial where
participants will be randomized either to the experimental or to the control group using
verified computer software. The experimental group will meet with the researcher to look
at their color Doppler ultrasound images taken during a graded treadmill test (GTT) at
different levels of pain. In contrast, the control group will perform the GTT without the
benefit of seeing their images afterwards. Both groups will undergo 12 weeks of at-home
exercise before reevaluation of their PAD. The ultrasound technicians will be blinded, but
the participants and principal investigators will not be given the nature of the
intervention. Due to the novelty of the intervention, three participants will undergo the
treadmill component of the study prior to the rest of the participants starting the study in
order to ensure protocol feasibility.
3.2 Study Population and Sampling
The study population will include English-speaking adults between 45 and 70
years old with IC PAD. The claudication pain must be in the calf, the most common
location of pain, and the disease burden must be in the popliteal artery, a common place
of atherosclerosis. The standard ABI/PVR diagnostic test performed at YNHH Heart and
Vascular (H&V) Center will be used to diagnose and locate the disease. The results will
be confirmed with an ultrasound image of the popliteal artery.
The YNHH H&V Center and New Haven area primary care clinics will be given
study details and asked to refer patients during a 16-month timeframe. Prior to
randomization, there will be a screening visit to determine whether patients meet
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inclusion and exclusion criteria. The screening visit will include a consent form
(Appendix A), an ABI/PVR, an ultrasound to confirm the disease burden in the popliteal
artery, the San Diego Claudication Questionnaire to confirm true intermittent
claudication symptoms (Appendix C), a history and physical exam to determine height,
weight, BMI, HbA1c, comorbid conditions, smoking status, number of medications,
number of diabetic medications, medication use of cilostazol or pentoxifylline, age, race,
and gender, and 6-minute walking distance (in meters) test to assess walking safety.1
3.3 Inclusion Criteria
The following criteria will be obtained at the screening appointment. Participants
must be PAD patients with disease burden in the popliteal artery and classic intermittent
claudication symptoms in the calf. PAD is defined as either an ABI <.90 at rest or <.73
after exercise. Intermittent claudication is pain that starts with exercise and diminishes
after rest. Patients must be able to ambulate safely during a 6-minute walking test (6MWT) and their distance must be limited by their claudication pain. Due to the
importance of sight in this protocol, participants must have intact vision, including the
ability to see color.
3.4 Exclusion Criteria
Patients without PAD (ABI >.90 at rest or >.73 after exercise), those unable to
provide an accurate ABI recording, and those who do not have disease burden in the
popliteal artery with associated calf pain will be excluded. Patients with no leg pain,
resting leg pain, critical limb ischemia, or acute limb ischemia will be excluded. Patients
with impairments that prevent walking on a treadmill, those without access to a safe
walking location, and those with exercise ability limited by factors other than
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claudication leg pain will be excluded. Participants who started cilostazol or
pentoxifylline within 3 months of the trial start are excluded. Patients with major
medical diseases such as chronic obstructive pulmonary disease, asthma, class III or IV
heart failure, angina, abnormal baseline stress test, active cancer, stroke or TIA in the past
3 months, liver failure, or renal failure will be excluded. Patients with uncontrolled
T2DM, defined as HbA1c >8%, will be excluded. Patients with an allergy to bioadhesive
tape will be excluded because this is needed for attaching the ultrasound probe to the leg.
3.5 Subject Protection and Confidentiality
Prior to recruitment, we will seek approval for the study from the Yale Human
Investigation Committee (HIC) Institutional Review Board (IRB). All participants must
provide written, informed consent prior to participating in the study. There are seven
components in our consent form: the purpose and procedures of the study, potential risks
or discomforts, potential benefits that can be expected from the research, alternatives that
may benefit the participant, a statement regarding confidentiality of information, contact
information in the event of questions, and a statement that research participation is
voluntary. Participants may drop out at any time and this will not impact their current or
future medical care.
The Yale 400 IRB Policy and Confidentiality of Human Health Research
Information document will be used to ensure protection of patient information. The study
will comply with current HIPAA regulations and only gather information that is needed
in order to accomplish the goal of the experiment. Participants must know who will
know about their participation in the study, how the data will be used, who will have
access to the data, how their information will be protected from those who should not
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have access, and how long the data will be retained. All information will be deidentified
as soon as possible and kept confidential within password-protected, encrypted servers.
Everyone involved with the study will complete the Human Subjects Protection Training
and HIPAA privacy training. No one involved in the study will have any financial
relationship with any component of the study that may create a conflict of interest.
Lastly, since our study takes place in New Haven, it is likely that some of the
eligible participants will be employees of YNHH. This eligible group of participants will
be informed that participation is not required, and it will not impact their employment or
performance evaluation. If the employee chooses to participate, the employee will not
experience any coercion and their privacy will be respected. All parts of the study will be
done out of sight of employees not directly involved in the study. If the employee
chooses not to participate, their supervisor will not be informed under any circumstance.
3.6 Recruitment
The YNHH H&V Center and New Haven area primary care clinics will be given
information about the study and flyers (Appendix D) to distribute to eligible participants.
Interested patients will be referred to the study. Additionally, the flyers will be mailed to
patients between 45 and 70 years old in the New Haven area and participants in prior
PAD studies. This study will not include financial compensation because we want to
limit the use of additional motivational tools in order attribute any effect to the imaging
intervention. Participants will be able to keep the Fitbit activity monitor given to them
during the study as compensation for their participation.

43

3.7 Experimental Protocol
Participants who meet criteria during the screening visit and sign the informed
consent to participate will be randomized to either the experimental or control arm of the
study. Three participants who meet criteria will undergo a trial of the GTT at the end of
the screening visit to ensure the feasibility of strapping the ultrasound probe to
participants’ legs for continuous imaging. After, all participants will be invited to the
YNHH H&V Center for the baseline visit. They perform the GTT and to fill out several
surveys. Prior to starting the treadmill test, ultrasound will be used to locate the stenosis
within the popliteal artery. Using Velcro straps and bioadhesive tape, the ultrasound
probe will be taped in place over the stenosis allowing for a continuous recording during
the test. The GTT will start at 2 mph and 0% grade and increase by 2% every two
minutes. At rest, mild, moderate, and severe claudication pain, the ultrasound technician
will record the peak systolic velocity (PSV) and take a color Doppler image of flow
through the popliteal artery. The treadmill grade and distances to mild, moderate, and
severe claudication pain will be measured in both groups. Claudication onset time will
also be measured. All distances will be measured in meters and all times in seconds. For
safety, a pulse oximetry device will be used to measure heart rate and oxygen saturation
throughout the treadmill test and periodic blood pressure recordings will be taken.
After the treadmill test, the principal researcher will show the experimental group
their color Doppler image recordings at rest and mild, moderate, and severe pain. The
researcher will explain that seeing color within the vasculature means there is blood flow.
More color means more blood flow, while less color means less blood flow, which is
what is contributing to their symptoms. Participants will be shown two sample images of
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what a healthy versus atherosclerotic vessel looks like (Appendix E) and be able to
compare them to their own imaging. Participants will be able to ask the researcher any
questions regarding their pain and associated imaging at this time.
Both experimental and control groups will meet with the researcher after the
treadmill test to get the standard of care instructions for the next 12 weeks and to ask any
questions that they have. All participants will be strongly encouraged to exercise to nearmaximal claudication pain three days a week for 45 minutes to start, but with increasing
frequency in the number of days overtime. Both groups will be given a Fitbit to wear
only during their walking exercise sessions and instructions on how to use it. The
number of steps during exercise each day will be recorded by the participant either by
writing it down or connecting it to an application on their phone.
During the clinic visit, the principal investigators will administer three
questionnaires to all participants. Health-related quality of life will be measured using
the 36-Item Short Form Survey Instrument (SF-36; Appendix F).2 The subcategories
within this survey are physical functioning, role limitations due to physical health
problems, bodily pain, general health perceptions, vitality, social functioning, role
limitations due to personal or emotional problems, and mental health. The survey is
scored from 0 to 100 with higher numbers representing a more favorable health state.
The second survey, the Walking Impairment Questionnaire (WIQ; Appendix G), assesses
walking distance, stair-climbing, and walking speed. Participants will rate how difficult
certain tasks are within these categories from 0 (unable to perform activity) to 4 (no
difficulty with activity).3 Questions within each category are weighted based on
difficulty in order to calculate a final score. Scores range from 0 to 100, with 0 being the
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most impaired. Lastly, the Fear-Avoidance Belief Questionnaire (FABQ; Appendix H)
will measure participants’ fear of their claudication pain and physical activity.4 The
FABQ determines how much physical activity and normal work impacts their leg pain.
Scores range from 0 to 96 with 96 corresponding to the highest level of fear-avoidance
beliefs. After completion of the treadmill test and questionnaires, participants will be
given a follow-up appointment for 12 weeks after.
At the follow-up visit, the GTT, questionnaires, and 6-MWT will be administered
again, but both groups will be shown their images after the treadmill test. They will also
be notified of any improvements in, distance to varying levels of claudication pain, PSV
through the popliteal artery, 6-MWT distances, and quality of life, fear beliefs, and
walking impairment scores. Participants will keep the Fitbit as compensation for
participating in the study. Figure 1 outlines the experimental protocol.
Figure 1. Experimental Protocol
Initial Visit After Screening
• Graded treadmill test
• Health-related quality of
life questionnaire
• Walking impairment
questionnaire
• Fear-avoidance
questionnaire

Screening Visit
•
•
•
•
•

Read/ask questions/sign
consent form
ABI/PVR, Ultrasound
San Diego Claudication
Questionnaire
History and Physical Exam
3 participants will trial the
graded treadmill test

Follow-up Visit
• Graded treadmill test
showing all participants
their vasculature
• Repeat 3 questionnaires
• Information on the
changes over time

Home Exercise
•

12 weeks
•
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Told to exercise to nearmaximal pain 3 times a
week for 45 minutes (with
increasing frequency
overtime)
Use a FitBit only during
exercise sessions to monitor
steps/day

3.8 Study Variables and Measures
The intervention will be visualizing color Doppler ultrasound imaging of the
popliteal artery taken during mild, moderate, and severe claudication pain.

Color

Doppler mode is a setting on the ultrasound device that allows for visualization of blood
flow through a vessel.5 It gives information regarding the presence of blood flow, the
direction of flow, and speed of flow.5 Figure 2 is an example of a color Doppler
ultrasound recording.
Figure 2: Color Doppler Ultrasound
Image of a Stenotic Popliteal Artery.5
There is blood flow towards and away
from the probe, as shown by the red and
blue colors.5 Since the lumen is not full
of color, this shows there is an
atherosclerotic occlusion.5

The patients in the control group will not visualize the popliteal artery on
ultrasound, but images will still be obtained. The primary dependent variable will be
claudication onset time (COT), in seconds, during the standard Yale GTT. Secondary
dependent variables include mean walking distances (MWD; in meters) to mild,
moderate, and severe claudication pain, 6-MWT distance (meters), peak systolic velocity
through the popliteal artery, average steps per day during the 12-week home exercise
component, health-related quality of life score, walking impairment score, and the fearavoidance score. All of these dependent variables will be measured at baseline and
follow-up except for average steps per day which will be measured throughout the
intervention.
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3.9 Blinding
The participants and the principal investigators will not be blinded to the
intervention, but the ultrasound technicians will be. The investigators need to know
which participants are in each group in order to show and explain the images, or not.
Similarly, the participants will not be blinded during the intervention because it will be
clear whether they are seeing their imaging or not. In fact, the study is centered on the
experimental group seeing their imaging. The ultrasound technicians are blinded because
they will take images of all of the participants during the GTT.
3.10 Assignment of Intervention
Assignment of participants to the experimental or control group will be
randomized by a computer program (SAS programming software). We will be using
stratified permuted block randomization. We will be stratifying based on HbA1c levels
since this is the largest potential confounder. Block randomization will be used to ensure
a balance in group sizes since the sample size is relatively small.
3.11 Adherence
The Fitbit will help monitor adherence to home exercise, as it will record daily
walking distances. Additionally, post-intervention graded treadmill walking performance
will indicate adherence to the home walking protocol. If participants are adherent to
exercising at home, the COT and other outcomes are expected to improve. Lastly, this
study requires relatively little time from the participants which should increase
adherence. It only requires three office visits which should all be less than an hour and a
half long. While it will take time for participants to exercise three times a week (or more
frequently overtime), this is something that should be incorporated into their daily life
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regardless of the study. All participants will receive free parking and the Fitbit for
compensation; this will be advertised on the flyer.
3.12 Monitoring of Adverse Events
In order to mitigate adverse events, only those who have a steady gait during the
6-MWT in the screening visit will be able to participate in the study. During the GTTs,
the participant will be told to notify the technician if they are experiencing any chest pain,
shortness of breath, lightheadedness, dizziness, or other symptoms that are new for them.
Pulse oximetry recordings will be taken continuously throughout the test to observe for
any hypoxemia or abnormally elevated/depressed heart rate. Blood pressure recordings
will be taken at baseline and periodically during the test to monitor for extreme
hypotension or hypertension. Showing participants their imaging after completion of the
treadmill test, instead of during it when they are experiencing the pain, will mitigate risks
during the treadmill test. If chest pain, shortness of breath, vision changes, hypoxemia,
extreme tachycardia or bradycardia, or concerning changes to blood pressure occurs, the
test will be stopped. While exercising at home, participants will be encouraged to call the
research assistant or medical provider if they experience any new or concerning
symptoms.
3.13 Data Collection
The screening appointment clinical and survey data will be collected by the
principal investigators and technicians will perform the ABI/PVR and ultrasound. The
technicians will also be responsible for all data collection during the treadmill test as well
as monitoring the patients’ vitals. We will attempt to limit the number of different
technicians administering the tests to avoid administration variability. The principal
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investigators will be responsible for explaining the standard at-home exercise protocol to
all participants. In addition, the principal investigator will show and explain the imaging
to the experimental group after the treadmill test (and to both groups at the follow-up
appointment). The investigator will distribute the three questionnaires during the initial
and follow-up visits and score them for feedback. This investigator will also obtain the
step logs or information from the participants’ phone applications at the follow-up
appointment. Having the principal investigator explain the ultrasound images, instead of
the ultrasound technicians, will allow for less variability in the explanations and for the
technicians to stay within their normal scope of practice. Participants will be responsible
for remembering to put on the Fitbit during their home exercise sessions.
3.14 Sample Size Calculation
We based our sample size calculation (Appendix I) on the difference in mean
claudication onset time (COT; in seconds) between the experimental and control groups
after a mobile health motivational exercise program among PAD patients in the Duscha
et al. trial.6 The experimental group experienced a 205 second increase in COT after the
intervention, which is well above the average of 99-132 seconds’ improvement in SET.6
We strive to create improvement that matches highly successful prior interventions. To
see a difference in COT of 205 seconds with a standard deviation of 256 seconds,
assuming an alpha of .05 and power of 80% with a 2-tailed hypothesis, we calculated a
required sample size of 44. Adjusting for a 10% expected drop-out rate and ensuring an
even number, we will recruit 50 participants to be randomized within our study.
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3.15 Analysis
The descriptive characteristics include age (years), weight (kg), height (inches),
BMI (kg/m2), number of medications, number of diabetic medications, HbA1c, 6-MWT
distance, and ABI with mean and standard deviation and gender, race, smoking status,
presence of hypertension, medication use of cilostazol or pentoxifylline in the past, and
presence of diabetes using relative frequencies. We will perform intention to treat
analysis. We will use a significance level of P<0.05 to look for differences among the
baseline characteristics. All of the primary and secondary outcomes are continuous
variables and will be presented as means with standard deviations. An independent
sample Student’s t test will be performed to determine if post-intervention changes from
baseline in primary and secondary outcomes are different between groups. ANCOVA
will be used to analyze mean changes in primary and secondary outcomes from baseline
within each group and adjust for confounders. Statistical significance is defined as
P<0.05.
3.16 Timeline and Resources
The recruitment process and experimental protocol will take two years. Prior to
recruitment, we expect the Human Investigation Committee (HIC) approval to take 2-3
months. After approval, the next 16 months will be used for a rolling recruitment and
study protocol until the target sample size is met. The first 3 eligible participants will test
the feasibility of continuous ultrasound recordings during the GTT. This feasibility test
will be a shortened version of the treadmill test during the screening appointment, just
long enough to ensure the probes will stay in place to obtain quality recordings. They
will need to sign an additional consent form (Appendix B). After the probe technique has
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been optimized to produce high quality images, other eligible participants will begin the
experimental protocol. The number of appointments per day and week will be limited by
technician availability. All of the initial appointments must be completed by 16 months
into the study to allow for 12 weeks of home exercise and the post-intervention
appointment. Upon completion of the study, we expect data analysis to take an additional
3 months; the HIC approval and data analysis are not included in the 2-year time frame.
The Principal Investigator (PI) will be Catherine Yeckel, PhD and the co-PI will
be Sarah Fittro, PA-SII. They will present the study to YNHH and Yale University
School of Medicine for approval and approach the YNHH H&V Center and local primary
care offices to hand out flyers. Sarah Fittro will be responsible for obtaining the
descriptive characteristic data during the screening appointment, showing the
experimental group their ultrasound images after the treadmill test, explaining the
standard of care exercise training to both groups, and administering the questionnaires.
Ultrasound technicians at the YNHH H&V Center will perform the ABI/PVR, find the
disease within the popliteal artery, administer the GTT, and operate the ultrasound
device. Two ultrasound technicians will be needed for each participant appointment to
allow for the responsibilities to be split up and increase accuracy. For example, one
technician will operate the treadmill and monitor vitals while the other technician
operates the ultrasound device. Currently, it is common for at least two ultrasound
technicians to be on-site at the YNHH H&V Center. There is already a treadmill within
the suite where technicians record an ABI after exercise, so no additional resources are
needed for this experiment. The technicians will just need to be trained on how to secure
the ultrasound probe during exercise.
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Chapter 4-Conclusion
IC PAD is a common debilitating disease worldwide.1 Exercise is known to
improve IC symptoms and PAD outcomes, but adherence is low due to fear of pain, lack
of disease knowledge, and poor perceived control over the disease.2-7 Adherence to SET
and HEPs is low due to cost and accessibility. Finding a way to increase adherence to
home exercise by mitigating these barriers is highly desirable. Imaging has been used
among other populations to increase exercise adherence.8 Whether an imaging strategy
offers a solution to increase exercise adherence in PAD patients is unknown. The
proposed study will use simple, color Doppler ultrasound images to enhance patients’
understanding of their PAD by showing how it impacts their affected leg during a
personalized, exercise-associated graded pain scale test. If successful, increased
understanding will alleviate fears regarding their pain and motivate them to exercise more
and to a higher pain level. This would allow for the motivational component to be given
early on in during the diagnosis appointment and prevent disease progression.
4.1 Advantages and Disadvantages
The main advantage of the proposed study is its novelty; using imaging to
increase exercise adherence breaks into a new realm of techniques to support PAD
patients. The data in using imaging to increase exercise adherence among the CAD
population is very promising and warrants investigation of imaging use among other
populations, such as PAD.8 The proposed study is advantageous compared to other PAD
exercise adherence studies because it addresses at least six reasons for lack of adherence:
cost, accessibility, efficiency, fear of claudication pain, lack of health understanding, and
lack of perceived control; other studies aimed to increase adherence have not been able to
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touch on all of these through one intervention. This intervention provides a feasible,
noninvasive, relatively inexpensive way for patients to actually visualize the impact of
disease on their body in order to motivate behavior changes early on in the disease
process. It also allows patients to visualize the resulting positive impact of their exercise
efforts at the subsequent vascular appointment. If effective, this intervention could be
used worldwide to decrease economic and health burdens.
While the novelty of this proposed study is an advantage, it also could be a
disadvantage. As with any new idea, it may come with unexpected challenges requiring
modification of the procedure. Additionally, ideally, we would have a double-blinded
study, but it is impossible to blind the participants or the investigators. The study is
centered on the experimental group seeing their ultrasound images. Next, the recruitment
process is on a volunteer basis, which means those who sign up may be more motivated
than the general population; it is hard to predict how this will impact the results. This
may even bias the results towards the null, making it more challenging to see a
difference; this would mean if the results are significant, they may be even stronger in the
general population. Lastly, it may be challenging to motivate exercise in the winter
months, especially among those who are low-income and do not belong to exercise
facilities. This is a reality of HEPs and requires a broader community solution.
4.2 Feasibility
One of the biggest advantages to this proposal is most of the needed resources already
exist at the YNHH Heart and Vascular Center. The ultrasound technicians are already
trained in ABI/PVRs, color Doppler ultrasonography, and graded treadmill tests and all
of the needed equipment is already there. The only training the technicians will need is
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how to strap the ultrasound probe to participants’ legs. Other studies have already
attached a device to participants’ legs in the same location, so we should be able to
replicate this in our design.9 As for cost, the study requires a Fitbit and several additional
appointments using ultrasound, ABI/PVR, and treadmill equipment. A Fitbit that
monitors activity is around $50.10 Spending relatively little upfront to control the disease
will decrease the need for money spent on medications and surgeries in the future. As for
timing, it may be challenging to recruit 50 participants who meet all of the criteria in less
than two years. This study is unique in that disease burden must be within the popliteal
artery due to proximity to the calf. While most of PAD burden is within the popliteal
artery, this does limit the population we can recruit from.11 However, we do not envision
this inhibiting recruitment completion because there is a large PAD burden within the
New Haven area. Lastly, this study does not require an extensive time commitment from
participants; it involves less than 5 hours of appointment time and daily home exercise.
While daily exercise will most likely be an adjustment for participants, this is important
for their health regardless of the study.
4.3 Clinical Significance
The medical community has not been successful in increasing exercise adherence
among PAD patients and the prevalence continues to rise due to increasing incidence in
risk factors such as diabetes.1,12 Due to the sedentary, high-calorie, and busy American
lifestyle, the prevalence of PAD is expected to remain high. Therefore, we need to
identify ways to better treat these patients early on in their disease, which the proposed
study is well-positioned to do. The IC PAD population is the perfect group of patients to
target because this stage is early on in the disease where behavioral changes can still
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make a difference. If this study is successful, it will decrease poor outcomes and the need
for more costly interventions such as surgery. It would be an easy intervention to
incorporate into the diagnostic appointment worldwide because it is simple, noninvasive,
and relatively low cost. This intervention offers a different route to obtain the same end
goal, improved symptoms and quality of life, that other studies have been trying to
achieve. It could be a way to not only produce change during the study, but also
sustained behavioral changes after the study.
4.4 Future Directions
This study has the potential to develop an innovative approach to increase
exercise adherence among PAD patients. A future direction that could take place after
the proposed study is, we could perform the study among those with atherosclerotic
burden within any lower extremity artery; eliminating this exclusion criterion would
allow for a larger sample size and easier recruitment. This future study would highlight
whether the proximity of the popliteal artery to the calf is a necessary component for
motivation. Moreover, patients with poorly controlled type 2 diabetes were excluded
from our initial trial. These patients would be a good target group for future focus. Most
importantly, this study will inform clinicians on how to best increase exercise adherence
among PAD patients, which is crucial right now as the prevalence is rising.
In conclusion, using ultrasound to show how PAD impacts the affected leg during
a personalized, exercise-associated graded pain scale test is a promising next step to
enhance adherence to exercise interventions. The results of the study will demonstrate a
means to achieve the extremely challenging task of inducing behavior change to improve
PAD outcomes and quality of life.
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Appendices
Appendix A. Sample HIC Full Consent form
Created using 200 FR.1 HIC Consent For Participation in a Research Project Template
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
200 FR.1 (2016-2)
YALE UNIVERSITY SCHOOL OF MEDICINE-YALE-NEW HAVEN
HOSPITAL
Study Title: Using Color Doppler Ultrasound to Promote Exercise in Adults with
Peripheral Artery Disease
Principal Investigator: Catherine Yeckel, MS, Ph.D.,
Co-Principal Investigator: Sarah Fittro PA-SII
Funding Source: [Insert name of company or agency]
Invitation to Participate and Description of Project
We are inviting you to participate in a research study designed to look at how
color Doppler ultrasound can be used to promote exercise among adults with peripheral
artery disease. You have been asked to participate because you are an adult with
peripheral artery disease and intermittent calf claudication pain and have expressed
interest to your primary care or cardiovascular provider. This will be a study with 50
participants. Preliminarily, we will need several participants to trial the treadmill portion
of the study. This is the novel component of the study, so we need to ensure the
feasibility prior to initiating the complete trial. If you are willing to volunteer for this,
please let us know; it will add about 20-30 minutes at the end of your screening
appointment.
In order to decide whether or not you wish to be a participant in this research
study you should know enough about its risks and benefits to make an informed decision.
This consent form gives you detailed information about the research study, which a
member of the research team will discuss with you. This discussion should go over all
aspects of this research: its purpose, the procedures that will be performed, any risks of
the procedures, possible benefits, and possible alternative treatments. Once you
understand the study, you will be asked if you wish to participate; if so, you will be asked
to sign this form.
Description of Procedures
Screening Appointment: Located at Yale New Haven Hospital Heart and Vascular
Center
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•

•
•
•

An ABI/PVR and ultrasound will be performed to confirm your disease burden is
within your popliteal artery; neither of these tests should induce any pain, they are
simple diagnostic tests using blood pressure cuffs and an ultrasound device to take
images of your blood vessels.
You will fill out the San Diego Claudication Questionnaire to confirm your
symptoms are typically considered intermittent claudication symptoms.
You will perform a 6-minute walking distance test to assess walking safety and
functional ability.
A provider will perform a basic history and physical exam to determine height,
weight, BMI, hemoglobin A1C level, other health conditions, smoking status,
medications, age, race, and gender.

Initial Visit After Screening: Located at Yale New Haven Hospital Heart and Vascular
Center
•

•
•
•

•
•
•

Each participant will perform a treadmill test where the incline gradually
increases while you walk. Using ultrasound, the place where the blood vessel in
your calf is not allowing enough blood flow will be marked with a marker.
Velcro and bioadhesive tape will be used to attach the ultrasound probe over this
spot to obtain continuous images and blood flow information during the test. The
treadmill test starts very slowing, at 2mph, 0% incline and will increase by 2%
grade every two minutes. You will be asked to tell the ultrasound technician
when you are experiencing mild, moderate, and severe calf pain. Some
participants will see their color Doppler ultrasound image at these points and
others will not; computer randomization will determine which group you are in.
Blood pressure, heart rate, and oxygen saturation will be measured throughout the
test for safety.
Those participants who will see their ultrasound image will be educated on the
very basics of what they will be seeing and the meaning of it prior to the graded
treadmill test.
The ultrasound technicians will know which participants are in each group, but
the investigators will be blind to this information.
You will be asked to fill out a health related quality of life survey with 36
questions that will look at your physical functioning, limitations due to health
problems, pain, health perceptions, vitality, social functioning, limitations due to
personal or emotional problems, and mental health.
You will be asked to fill out the 22 question Walking Impairment Questionnaire
that assesses walking distance, stair-climbing, and walking speed.
You will be asked to fill out the 16 question Fear-Avoidance Belief Questionnaire
(FABQ) which measures your fear of your claudication pain and physical activity.
You will be given a FitBit and instructions on how to use it while exercising at
home.
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Home Exercise:
•
•
•

You will be told to exercise at home 3 times a week (or more overtime) for 45
minutes for 12 weeks. If you reach maximal claudication pain during exercise,
you may stop temporarily until pain dissipates.
You will wear the provided FitBit only during exercise to monitor your steps/day.
You will record your number of steps/day by writing it down or connecting the
FitBit to a phone application to automatically collect the data.

Follow-Up Visit: Located at Yale New Haven Hospital Heart and Vascular Center
•
•
•
•

You will perform the same treadmill test and 6-minute walk test again. You will
also fill out the same three questionnaires again.
During this treadmill test everyone will be shown their vasculature on ultrasound
and will be notified of any changes in how long they can walk until they
experience different levels of pain.
You will be notified of any change in distance walked during the 6-minute walk
test.
You will be notified of any changes to your quality of life, fear beliefs, and
walking impairment scores.

Overall:
•

•
•

The study consists of three appointments at YNHH, ranging from about 1-2 hours
long, where you will undergo diagnostic tests, fill out questionnaires, perform a 6minute walk test, and perform a graded treadmill test. You will be instructed to
exercise at home to near-maximal claudication pain for 12 weeks prior to coming
back in for follow-up tests.
After screening is complete, the entire protocol will span over 5-6 months.
A computer randomization program will determine whether participants will see
their vasculature on ultrasound with their claudication pain during the graded
treadmill test or not.

A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as
required by U.S. Law. This website will not include information that can identify you.
At most, the website will include a summary of the results. You can search this website
at any time.
You will be told of any significant new findings that are developed during the course of
your participation in this study that may affect your willingness to continue to participate.
Risks and Inconveniences
•

Exercising on the treadmill and at home comes with risks, but we hope to
minimize these risks in several different ways:
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•
•

•

o During the treadmill test, medical professionals will be monitoring your
blood pressure, pulse, and oxygen saturation.
o You will be expected to wear sneakers and exercise clothing to limit
mechanical falls while exercising.
o Those with chronic obstructive pulmonary disease, asthma, class III or IV
heart failure, angina, an abnormal baseline stress test, or difficulty
balancing while walking will not be eligible for the study.
o If you experience concerning symptoms during the treadmill test, the test
will be stopped and appropriate interventions will occur to ensure the
health and safety of the participant.
o You will be given the number of a provider to call if you experience
symptoms while exercising at home.
While exercising on the treadmill and at home, you will experience mild to severe
claudication pain which will feel uncomfortable. However, experiencing this pain
is a necessary component to our study and does not put you in danger.
If you are an employee of YNHH or Yale University, your privacy will be
respected. All parts of the study will be done out of sight of any other employees
not directly involved in the study. If you choose not to participate, your employer
will not be notified and in no way will this impact your performance evaluation.
You will need to come to YNHH for 3 appointments ranging from 1-2 hours long;
parking will be free for these appointments.

Benefits:
•

•

This research may show the role of imaging in improving exercise adherence in
adults with peripheral artery disease. Imaging may be a way to decrease the
amount of medications and surgical interventions needed, decrease claudication
pain associated fear, and improve health-related quality of life among adults with
peripheral artery disease.
We expect this study to benefit society at large by advancing scientific
knowledge.

Economic Considerations
•
•
•

You will be reimbursed for parking fees at YNHH for the three required
appointments. Transportation costs to get you to YNHH will not be covered by
the research study.
You will be allowed to keep the FitBit provided to you during the study.
The screening ABI/PVR and ultrasound, screening history and physical exam,
monitored graded treadmill test, and monitored 6-minute walk test will be
provided at no cost to you.

Treatment Alternatives/Alternatives
•

Other treatment options to improve claudication symptoms and secondary
outcomes are supervised exercise training, cilostazol, multi-drug regimens (anti-
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platelet medications, lipid lowering medications, and blood pressure medications),
and surgery. These treatments will not be used in this study.
Confidentiality
•
•
•

•
•

Your data will be de-identified within 1 week of acquisition of all study data and
it will remain unidentified indefinitely.
All study data will be recorded on the computer and password protected.
ABI/PVR results, ultrasound recordings, height, weight, BMI, hgb A1C,
comorbid conditions, medications, age, race, and sex will be entered into your
Electronic Medical Record (EMR) and will therefore be accessible to future
providers who are in your EMR. Information within your EMR may also be
shared with others who are appropriate to have access to your EMR (e.g. health
insurance companies, disability provider).
Only information that is necessary to complete the study will be collected.
If you choose to have your FitBit connected to a phone application to record the
data, only you will have access to this application. Research investigators will
ask you to show this data at the follow-up appointment. They will only need the
total number of steps for the three months, provided by the monthly summaries in
the application.

Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
State law. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases. When the results of the
research are published or discussed in conferences, no information will be included that
would reveal your identity unless your specific permission for this activity is obtained.
Representatives from Yale University, the Yale Human Research Protection Program,
and the Yale Human Investigation Committee (the committee that reviews, approves, and
monitors research on human subjects) may inspect study records during internal auditing
procedures. However, these individuals are required to keep all information confidential.
In Case of Injury
If you are injured while on the study, seek treatment and contact the study doctor as soon
as you are able.
Yale School of Medicine and Yale-New Haven Hospital do not provide funds for the
treatment of research-related injury. If you are injured as a result of your participation in
the study, treatment will be provided. You or your insurance carrier will be expected to
pay the costs of this treatment. No additional financial compensation for injury or lost
wages is available.
You do not give up any of your legal rights by signing this form.
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Voluntary Participation and Withdrawal
•
•

You will have the ability to withdraw your data from the research, but only before
it has been de-identified one week after data collection is complete.
If you have required medical needs upon withdrawal, these should be stated. Any
follow-up procedures or assessments accompanying the withdrawal should be
clearly explained.

You are free to choose not to participate. If you do decide to become a subject, you are
free to withdraw from this study at any time during its course. Refusing to participate or
withdrawing from the study will involve no penalty or loss of benefits to which you are
otherwise entitled (such as health care outside the study, payment for your healthcare,
and your health care benefits). If you decide not to participate or you withdraw, it will
not harm your relationship with your own doctors or with Yale-New Haven Hospital.
We would still offer other treatment options.
The researchers may withdraw you from the research study if you develop serious side
effects or are noncompliant.
Questions
We have used some technical terms in this form. Please feel free to ask about
anything you don’t understand and to consider this research and consent form carefully –
as long as you feel necessary – before you make a decision.
Authorization and Consent
I have read (or someone has read to me) this form and have decided to participate in the
project described above. In general purposes, the particulars of my involvement and
hazards and inconveniences have been explained to my satisfaction. My signature also
indicates that I have received a copy of this consent form.
By signing this form, I give permission to the researchers to use (and give out)
information about myself for the purpose described in this form. By refusing to give
permission, I understand that I will not be able to be in this research.
Name of Subject:
Signature:
Relationship:
Date:

Signature of Principal Investigator/Person Obtaining Consent
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Date

If you have further questions about this project of if you have a research-related
problem, you may contact the Co-Principal Investigator, Sarah Fittro PA-SII at (xxx)xxx-xxxx or the Principal Investigator, Catherine Yeckel, Ph.D. at (xxx)-xxx-xxxx.
If after you have signed this form you have any questions about your privacy
rights, please contact the Yale Privacy Officer at 203-432-5919.
If you would like to talk with someone other than the researchers to discuss
problems, concerns, and questions you may have concerning this research, or to discuss
your rights as a research subject, you may contact the Yale Human Investigation
Committee at 203-785-4688.
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Appendix B. Sample HIC Preliminary Treadmill Test Consent Form
Created using 200 FR.1 HIC Consent For Participation in a Research Project Template
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
200 FR.1 (2016-2)
YALE UNIVERSITY SCHOOL OF MEDICINE-YALE-NEW HAVEN
HOSPITAL
Study Title: Using Color Doppler Ultrasound to Promote Exercise in Adults with
Peripheral Artery Disease
Principal Investigator: Catherine Yeckel, MS, Ph.D.,
Co-Principal Investigator: Sarah Fittro PA-SII
Funding Source: [Insert name of company or agency]
Invitation to Participate and Description of Project
You have already consented to participate in a research study designed to look at
how color Doppler ultrasound can be used to promote exercise among adults with
peripheral artery disease. The study will consist of 50 participants, but several early
enrolled participants will be asked to trial the treadmill portion of the study which is
the basis of this consent form.
In order to decide whether or not you wish to be a participant in this research
study you should know enough about its risks and benefits to make an informed decision.
This consent form gives you detailed information about the research study, which a
member of the research team will discuss with you. This discussion should go over all
aspects of this research: its purpose, the procedures that will be performed, any risks of
the procedures, possible benefits, and possible alternative treatments. Once you
understand the study, you will be asked if you wish to participate; if so, you will be asked
to sign this form.
Description of Procedures
Graded Treadmill Test: Located at Yale New Haven Hospital Heart and Vascular
Center
• You have already been deemed eligible for the study during the screening
appointment; this treadmill test will occur at the end of the same appointment and
will add approximately 30 minutes.
• Using ultrasound, the place where the blood vessel in your calf is not allow
enough blood flow will be marked with a marker on your leg. Using Velcro
straps and bioadhesive tape, the color Doppler ultrasound probe will be put over
this spot to allow for continuous images and blood flow recordings as you
complete the treadmill test.
• The treadmill test starts very slowly, at 2mph, 0% incline and will increase by 2%
grade every two minutes. You will be asked to tell the technician when you are
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•

experiencing mild, moderate, and severe calf pain. Blood pressure, heart rate, and
oxygen saturation will be measured throughout the test for safety.
It will not impact which group you are randomized to afterwards as the computer
is responsible for this randomization.

A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as
required by U.S. Law. This website will not include information that can identify you.
At most, the website will include a summary of the results. You can search this website
at any time.
You will be told of any significant new findings that are developed during the course of
your participation in this study that may affect your willingness to continue to participate.
Risks and Inconveniences
•

•
•

Exercising on the treadmill comes with risks, but we hope to minimize these risks
in several different ways:
o During the treadmill test, medical professionals will be monitoring your
blood pressure, pulse, and oxygen saturation.
o You will be expected to wear sneakers and exercise clothing to limit
mechanical falls while exercising.
o Those with chronic obstructive pulmonary disease, asthma, class III or IV
heart failure, angina, an abnormal baseline stress test, or difficulty
balancing while walking will not be eligible for the study.
o If you experience concerning symptoms during the treadmill test, the test
will be stopped and appropriate interventions will occur to ensure the
safety and health of the participant.
While exercising on the treadmill, you will experience mild to severe claudication
pain which will feel uncomfortable. However, experiencing this pain is a
necessary component to our study and does not put you in any danger.
If you are an employee of YNHH or Yale University, your privacy will be
respected. The treadmill test will be done out of sight of any other employees not
directly involved in the study. If you choose not to participate, your employer
will not be notified and in no way will this impact your performance evaluation.

Benefits:
•

Ensuring the graded treadmill component is properly designed is a critical part of
this study. Allowing for this to happen will help the study be as effective as
possible.

Economic Considerations
•

You will be reimbursed for parking fees at YNHH for the appointment. You will
not have to come to the hospital an additional time for this treadmill trial, it will
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•

be part of the screening appointment. Transportation costs to get you to YNHH
will not be covered by the research study.
The monitored graded treadmill test will be provided at no cost to you.

Confidentiality
•
•
•

•

Your data will be de-identified within 1 week of acquisition of all study data and
it will remain unidentified indefinitely.
All study data will be recorded on the computer and password protected.
The ultrasound recordings will be entered into your Electronic Medical Record
(EMR) and will therefore be accessible to future providers who are in your EMR.
Information within your EMR may also be shared with others who are appropriate
to have access to your EMR (e.g. health insurance companies, disability
provider).
Only information that is necessary to complete the study will be collected.

Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
State law. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases. When the results of the
research are published or discussed in conferences, no information will be included that
would reveal your identity unless your specific consent for this activity is obtained.
Representatives from Yale University, the Yale Human Research Protection Program,
and the Yale Human Investigation Committee (the committee that reviews, approves, and
monitors research on human subjects) may inspect study records during internal auditing
procedures. However, these individuals are required to keep all information confidential.
In Case of Injury
Yale School of Medicine and Yale-New Haven Hospital do not provide funds for the
treatment of research-related injury. If you are injured as a result of your participation in
the study, treatment will be provided. You or your insurance carrier will be expected to
pay the costs of this treatment. No additional financial compensation for injury or lost
wages is available.
You do not give up any of your legal rights by signing this form.
Voluntary Participation and Withdrawal
•
•

You will have the ability to withdraw your data from the research, but only before
it has been de-identified one week after data collection is complete.
If you have required medical needs upon withdrawal, these should be stated. Any
follow-up procedures or assessments accompanying the withdrawal should be
clearly explained.
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You are free to choose not to participate. If you do decide to become a subject, you are
free to withdraw from this study at any time during its course. Refusing to participate or
withdrawing from the study will involve no penalty or loss of benefits to which you are
otherwise entitled (such as health care outside the study, payment for your healthcare,
and your health care benefits). If you decide not to participate or you withdraw, it will
not harm your relationship with your own doctors or with Yale-New Haven Hospital.
We would still offer other treatment options.
The researchers may withdraw you from the research study if you develop serious side
effects or are noncompliant.
Questions
We have used some technical terms in this form. Please feel free to ask about
anything you don’t understand and to consider this research and permission form
carefully – as long as you feel necessary – before you make a decision.
Authorization and Consent
I have read (or someone has read to me) this form and have decided to participate in the
project described above. In general purposes, the particulars of my involvement and
hazards and inconveniences have been explained to my satisfaction. My signature also
indicates that I have received a copy of this consent form.
By signing this form, I give permission to the researchers to use (and give out)
information about myself for the purpose described in this form. By refusing to give
permission, I understand that I will not be able to be in this research.
Name of Subject:
Signature:
Relationship:
Date:

Signature of Principal Investigator/Person Obtaining Consent

Date

If you have further questions about this project of if you have a research-related
problem, you may contact the Co-Principal Investigator, Sarah Fittro PA-SII at (xxx)xxx-xxxx or the Principal Investigator, Catherine Yeckel, Ph.D. at (xxx)-xxx-xxxx.
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If after you have signed this form you have any questions about your privacy
rights, please contact the Yale Privacy Officer at 203-432-5919.
If you would like to talk with someone other than the researchers to discuss
problems, concerns, and questions you may have concerning this research, or to discuss
your rights as a research subject, you may contact the Yale Human Investigation
Committee at 203-785-4688.
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Appendix C. San Diego Claudication Questionnaire1
R

L

1. Do you get pain in either leg or
either buttock on walking? If no,
or uncertain, stop.

No…….
Yes.......
Uncertain…….

1
2
9

1
2
9

2. Does this pain ever begin when
you are standing still or sitting?

No…….
Yes.......
Uncertain.......

1
2
9

1
2
9

No.......
Yes......
No........
Yes......
No.......
Yes.......

1
2
1
2
1
2

1
2
1
2
1
2

4. Do you get it when you walk
uphill or hurry?

No…….
1
Yes……
2
Never walks uphill… 3

1
2
3

5. Do you get it when you walk at
an ordinary pace on the level?

No…….
Yes……
Uncertain…..

1
2
9

1
2
9

6. Does the pain ever disappear
while you are walking?

No……
Yes…..
Uncertain…..

1
2
9

1
2
9

7. What do you do if you get it
when you walking?

Stop or slow down…. 1
Carry on….
2

1
2

8. What happens to it if you stand
still? If unchanged, stop.

Lessens or relieved… 1
Unchanged…
2

1
2

9. How soon?

10 minutes or less… 1
More than 10 minutes.2

1
2

3. In what part of the leg or buttock
do you feel it?
a. Pain includes calf/calves
b. Pain includes thigh/thighs
c. Pain includes buttocks
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Appendix D. Recruitment Flyer2,3

Volunteers Needed for
Research on Peripheral
Artery Disease
Do you have pain in your
calves when walking? You
may be eligible for a study that
could improve your symptoms
and overall health.

Participation Involves:
• Three appointments at
Yale New Haven
Hospital that involve
questionnaires, treadmill
tests, and diagnostics
• 12 weeks of home
exercise

You May Qualify If You:
• Have calf pain when
walking
• Do not have asthma,
COPD, heart failure, or
coronary artery disease
• Have not recently started
medications to help with
the calf pain

•
•

Compensation
You will use a FitBit during the study and keep it
as compensation
Free Parking at Yale-New Haven Hospital

FOR MORE INFORMATION:
Please contact Sarah Fittro at (xxx)-xxx-xxxx or
Email: sarah.fittro@yale.edu
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Appendix E. Healthy Versus Atherosclerotic Color Doppler Ultrasound4

This is a healthy artery. The vessel is fully filled with
blood moving in the same direction represented by the red
color filling the vessel walls. This is not seen in the
affected vessels of peripheral artery disease patients.

This is an unhealthy artery. Only a little bit of blood is passing
through the vessel presented by the small portion of red color.
The rest of the vessel is filled with plaque which is preventing
adequate blood flow. This is seen in patients with peripheral
artery disease.
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Appendix F. Health-Related Quality of Life Short Form-36 Questionnaire5

SF-36 QUESTIONNAIRE
Name:____________________

Ref. Dr:___________________

Date: _______

Age: _______

Gender: M / F

ID#: _______________

Please answer the 36 questions of the Health Survey completely, honestly, and without
interruptions.
GENERAL HEALTH:
In general, would you say your health is:
Excellent
Very Good

Good

Fair

Poor

Compared to one year ago, how would you rate your health in general now?
Much better now than one year ago
Somewhat better now than one year ago
About the same
Somewhat worse now than one year ago
Much worse than one year ago
LIMITATIONS OF ACTIVITIES:
The following items are about activities you might do during a typical day. Does your health
now limit you in these activities? If so, how much?
Vigorous activities, such as running, lifting heavy objects, participating in strenuous
sports.
Yes, Limited a lot
Yes, Limited a Little
No, Not Limited at all
Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or
playing golf
Yes, Limited a Lot
Yes, Limited a Little
No, Not Limited at all
Lifting or carrying groceries
Yes, Limited a Lot

Yes, Limited a Little

No, Not Limited at all

Climbing several flights of stairs
Yes, Limited a Lot
Yes, Limited a Little

No, Not Limited at all

Climbing one flight of stairs
Yes, Limited a Lot

Yes, Limited a Little

No, Not Limited at all

Bending, kneeling, or stooping
Yes, Limited a Lot

Yes, Limited a Little

No, Not Limited at all
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Walking more than a mile
Yes, Limited a Lot

Yes, Limited a Little

No, Not Limited at all

Walking several blocks
Yes, Limited a Lot

Yes, Limited a Little

No, Not Limited at all

Walking one block
Yes, Limited a Lot

Yes, Limited a Little

No, Not Limited at all

Bathing or dressing yourself
Yes, Limited a Lot

Yes, Limited a Little

No, Not Limited at all

PHYSICAL HEALTH PROBLEMS:
During the past 4 weeks, have you had any of the following problems with your work or other
regular daily activities as a result of your physical health?
Cut down the amount of time you spent on work or other activities
Yes
No
Accomplished less than you would like
Yes
No
Were limited in the kind of work or other activities
Yes
No
Had difficulty performing the work or other activities (for example, it took extra effort)
Yes
No
EMOTIONAL HEALTH PROBLEMS:
During the past 4 weeks, have you had any of the following problems with your work or other
regular daily activities as a result of any emotional problems (such as feeling depressed or
anxious)?
Cut down the amount of time you spent on work or other activities
Yes
No
Accomplished less than you would like
Yes
No
Didn't do work or other activities as carefully as usual
Yes
No
SOCIAL ACTIVITIES:
Emotional problems interfered with your normal social activities with family, friends,
neighbors, or groups?
Not at all
Slightly
Moderately
Severe
Very Severe
PAIN:
How much bodily pain have you had during the past 4 weeks?
None
Very Mild
Mild
Moderate
Severe
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Severe

Very

During the past 4 weeks, how much did pain interfere with your normal work
(including both work outside thehome and housework)?
Not at all
A little bit
Moderately
Quite a bit
Extremely

ENERGY AND EMOTIONS:
These questions are about how you feel and how things have been with you during the last 4
weeks. For each question, please give the answer that comes closest to the way you have
been feeling.
Did you feel full of pep?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit of the time
None of the Time
Have you been a very nervous person?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit of the time
None of the Time
Have you felt so down in the dumps that nothing could cheer you up?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit of the time
None of the Time
Have you felt calm and peaceful?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit of the time
None of the Time
Did you have a lot of energy?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit of the time
None of the Time
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Have you felt downhearted and blue?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit of the time
None of the Time

Did you feel worn out?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit of the time
None of the Time
Have you been a happy person?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit of the time
None of the Time
Did you feel tired?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit of the time
None of the Time
SOCIAL ACTIVITIES:
During the past 4 weeks, how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting with friends, relatives,
etc.)?
All of the time
Most of the time
Some of the time
A little bit of the time
None of the Time
GENERAL HEALTH:
How true or false is each of the following statements for you?
I seem to get sick a little easier than other people
Definitely true
Mostly true
Don't know
Definitely false
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Mostly false

I am as healthy as anybody I know
Definitely true
Mostly true
Definitely false

Don't know

Mostly false

I expect my health to get worse
Definitely true
Mostly true
Definitely false

Don't know

Mostly false

My health is excellent
Definitely true
Definitely false

Don't know

Mostly false

Mostly true
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Appendix G. Walking Impairment Questionnaire6
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Appendix H. Fear-Avoidance Beliefs Questionnaire (FABQ)7
Fear-Avoidance Beliefs Questionnaire (FABQ)
Here are some of the things which other patients have told us about their pain. For each
statement please circle any number from 0 to 6 to say how much physical activities such as
bending, lifting, walking or driving affect or would affect your back pain.
Completely
Disagree
1. My pain was caused by physical activity……………………… 0
1 2
2. Physical activity makes my pain worse……………………….. 0
1 2
3. Physical activity might harm my back………………………… 0
1 2
4. I should not do physical activities which (might) make
my pain worse…………………………………………………….. 0
1 2
5. I cannot do physical activities which (might) make my
pain worse….................................................................................. 0
1 2

Completely
Agree
6
6
6

Unsure
3
3
3

4 5
4 5
4 5

3

4 5

6

3

4 5

6

The following statements are about how your normal work affects or would affect your back
pain
Completely
Disagree
6. My pain was caused by my work or by an accident at work…. 0
1 2
7. My work aggravated my pain………………………………….. 0
1 2
8. I have a claim for compensation for my pain…………………. 0
1 2
9. My work is too heavy for me………………………………….. 0
1 2
10. My work makes or would make my pain worse.……………. 0
1 2
11. My work might harm my back……………………………….. 0
1 2
12. I should not do my normal work with my present pain…….... 0
1 2
13. I cannot do my normal work with my present pain………….. 0
1 2
14. I cannot do my normal work till my pain is treated…………... 0
1 2
15. I do not think that I will be back to my normal work
within 3 months…………………………………………………… 0
1 2
16. I do not think that I will ever be able to go back to that work… 0
1 2
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Completely
Unsure
Agree
3
4 5
6
3
4 5
6
3
4 5
6
3
4 5
6
3
4 5
6
3
4 5
6
3
4 5
6
3
4 5
6
3
4 5
6
3
3

4 5
4 5

6
6

Appendix I. Sample Size Calculation
Data from the Duscha Study8 (n=20):
Standard of Care/Control Group:
•
•
•

Pre-intervention mean claudication onset time: 252±256s
Post-intervention mean claudication onset time: 231±196s
Mean difference: -21s

Mobile Health/Experimental Group:
•
•
•

Pre-intervention mean claudication onset time: 320±226s
Post-intervention mean claudication onset time: 525±252s
Mean difference: 205s

Sample size calculation based on a t-test for 2 independent samples with common
variance:
Alpha (level of confidence, ): .05 (two-tailed hypothesis)
B (Type II error, ): .18, therefore, 82% power
Effect size based on mean differences among the two populations: -21s and 205s

N=44 (22 per group)
Factoring in a 10% drop-out and ensuring an even number of subjects to make
groups even results in a required sample size of n = 50.
Power and Precision, Version 4.0. Biostat.Inc. Englewood, New Jersey was used for
calculation.
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